SPRY posted a 6% gain on the week to $6.30, but the real story is what's happening in the lending market — short interest remains near 22% of the free float, borrow availability is close to fully used, and the stock fell 6.6% the day after its most recent earnings print.
The borrow picture is the sharpest signal right now. Availability has tightened dramatically over the past 30 days, running at just 6.4% — meaning for every 100 shares already borrowed, only about six remain available to lend. That marks a genuine squeeze on the lending pool; earlier in August, availability briefly fell below 1% on multiple days, a level where essentially every share in the pool was out on loan. The week brought some relief, with availability roughly doubling from those extreme lows, but the structural pressure remains. Cost to borrow has eased — down about 21% on the week to 2.8% — reflecting that brief loosening, though the trend over the past month is still elevated relative to where it started the summer.
Short interest itself tells a story of gradual retreat. Bears have trimmed positions modestly — short interest fell about 3.3% over the week to roughly 21.7 million shares, or 22% of the float. That follows a heavier short load through July, when the position was closer to 23 million shares. The direction of travel is bearish pressure easing, not reversing. ORTEX's short score sits at 82.6, deep in the upper percentile of the universe, and the stock ranks in the first percentile for both availability tightness and days-to-cover — factors that collectively frame a lending market that has very little slack left. Options positioning adds a nuance: the put/call ratio dropped to 0.20, near its lower range and well below its 52-week zone, suggesting options traders are not aggressively buying downside protection despite the elevated short interest.
The Street remains uniformly bullish on paper, but there is a widening gap between where analysts think SPRY should trade and where it actually is. The consensus mean price target is $23.25 — more than three times the current $6.30 price. The most recent action came from Leerink Partners in late June, which shaved its target from $25 to $24 while keeping an Outperform rating. Cantor Fitzgerald had previously lifted its target from $12 to $30 back in May, a move that reflected optimism around the Neffy commercial rollout. The bull case centres on Neffy's potential to disrupt the epinephrine market as the first needle-free anaphylaxis treatment, with the pricing structure seen as advantageous over auto-injectors. Bears focus on the pace of formulary wins and the risk that physician adoption trails expectations. EPS surprise ranks in the 78th percentile, a sign the company has managed to beat low expectations, but forward earnings momentum scores are weak — 26th percentile on 30-day EPS momentum and 18th on 90-day — reflecting a market that isn't rushing to revise estimates higher.
Institutionally, the holder base skews toward specialist healthcare funds rather than generalists. RA Capital (10.9% of shares), OrbiMed (8.3%), and Rubric Capital (8.0%) are the largest fund holders, with Rubric notably adding 1.8 million shares as of the last Q1 filing. On the other side, Millennium trimmed by 3.5 million shares over Q2. The insider register is net positive over the trailing 90 days in terms of share count, but all of the disclosed trades in recent quarters have been sells — the CEO, CMO, CFO, and COO all sold shares in the $8–15 range during 2025, well above today's $6.30 price. That context matters: insiders were sellers at prices significantly higher than where the stock trades today.
The next scheduled earnings event lands on November 10. The most recent print on August 13 produced a single-day drop of 6.6%, underlining that binary risk around results remains meaningful. Between now and then, the key variable to watch is whether formulary coverage decisions translate into prescription volume data that validates or challenges the Neffy rollout thesis — that, rather than short covering or analyst target adjustments, is what determines whether the 3x gap between price and consensus target starts to narrow.
See the live data behind this article on ORTEX.
Open SPRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
